Trials / Completed
CompletedNCT00335166
SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease
A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 330 (estimated)
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 as monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pardaprunox | 12-42 mg |
| DRUG | pramipexole | 1.5-4.5 mg |
| DRUG | Placebo Comparator | Placebo |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2008-02-01
- Completion
- 2008-02-01
- First posted
- 2006-06-09
- Last updated
- 2008-04-03
Locations
89 sites across 18 countries: United States, Australia, Czechia, Estonia, France, Germany, India, Italy, Lithuania, Malaysia, Netherlands, Poland, Portugal, South Africa, Spain, Taiwan, Thailand, United Kingdom
Source: ClinicalTrials.gov record NCT00335166. Inclusion in this directory is not an endorsement.